In conclusion, the combination of orthosteric and allosteric BCR-ABL1 inhibitors holds great promise for overcoming resistance in CML and ALL treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.